Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX plus nivolumab and ipilimumab with intrahepatic oxaliplatin for non-resectable colorectal liver metastases
2019-004397-26Phase 2Terminated
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil, folinic acid, nivolumab and ipilimumab in colorectal cancer (CRC), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Disease-free survival at 3 years without liver surgery/RFA. Started Dec 2019; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-004397-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004397-26.